BACKGROUND: The previous works about safety evaluation for constructed bladder tissue specific adenovirus are poorly documented. Thus, we investigated the biodistribution and body toxicity of bladder specific oncolytic adenovirus Ad-PSCAE-UPII-E1A (APU-E1A) and Ad-PSCAE-UPII-E1A-AR (APU-E1A-AR), providing meaningful information prior to embarking on human clinical trials. MATERIALS AND METHOD: Conditionally replicate recombinant adenovirus (CRADs) APU-E1A, APU-EIA-AR were constructed with bladder tissue specific UroplakinII(UPII) promoter to induce the expression of Ad5E1A gene and E1A-AR fusing gene, and PSCAE was inserted at upstream of promoter to enhance the function of promoter. Based on the cytopathic and anti-tumor effect of bladder cancer, these CRADs were intratumorally injected into subcutaneous xenografts tumor in nude mice. We then determined the toxicity through general health and behavioral assessment, hepatic and hematological toxicity evaluation, macroscopic and microscopic postmortem analyses. The spread of the transgene E1A of adenovirus was detected with RT-PCR and Western blot. Virus replication and distribution were examined with APU-LUC administration and Luciferase Assay. RESULTS: General assessment and body weight of the animals did not reveal any alteration in general behavior. The hematological alterations of groups which were injected with 5x10(8) pfu or higher dose (5x10(9) pfu) of APU-E1A and APU-E1A-AR showed no difference in comparison with PBS group, and only slight increased transaminases in contrast to PBS group at 5x10(9) pfu of APU-E1A and APU-E1A-AR were observed. E1A transgene did not disseminate to organs outside of xenograft tumor. Virus replication was not detected in other organs beside tumor according to Luciferase Assay. CONCLUSIONS: Our study showed that recombinant adenovirus APU-E1A-AR and APU-E1A appear safe with 5x10(7) pfu and 5x10(8) pfu intratumorally injection in mice, without any discernable effects on general health and behavior.
BACKGROUND: The previous works about safety evaluation for constructed bladder tissue specific adenovirus are poorly documented. Thus, we investigated the biodistribution and body toxicity of bladder specific oncolytic adenovirus Ad-PSCAE-UPII-E1A (APU-E1A) and Ad-PSCAE-UPII-E1A-AR (APU-E1A-AR), providing meaningful information prior to embarking on human clinical trials. MATERIALS AND METHOD: Conditionally replicate recombinant adenovirus (CRADs) APU-E1A, APU-EIA-AR were constructed with bladder tissue specific UroplakinII(UPII) promoter to induce the expression of Ad5E1A gene and E1A-AR fusing gene, and PSCAE was inserted at upstream of promoter to enhance the function of promoter. Based on the cytopathic and anti-tumor effect of bladder cancer, these CRADs were intratumorally injected into subcutaneous xenografts tumor in nude mice. We then determined the toxicity through general health and behavioral assessment, hepatic and hematological toxicity evaluation, macroscopic and microscopic postmortem analyses. The spread of the transgene E1A of adenovirus was detected with RT-PCR and Western blot. Virus replication and distribution were examined with APU-LUC administration and Luciferase Assay. RESULTS: General assessment and body weight of the animals did not reveal any alteration in general behavior. The hematological alterations of groups which were injected with 5x10(8) pfu or higher dose (5x10(9) pfu) of APU-E1A and APU-E1A-AR showed no difference in comparison with PBS group, and only slight increased transaminases in contrast to PBS group at 5x10(9) pfu of APU-E1A and APU-E1A-AR were observed. E1A transgene did not disseminate to organs outside of xenograft tumor. Virus replication was not detected in other organs beside tumor according to Luciferase Assay. CONCLUSIONS: Our study showed that recombinant adenovirus APU-E1A-AR and APU-E1A appear safe with 5x10(7) pfu and 5x10(8) pfu intratumorally injection in mice, without any discernable effects on general health and behavior.
Authors: J Nemunaitis; C Cunningham; A Buchanan; A Blackburn; G Edelman; P Maples; G Netto; A Tong; B Randlev; S Olson; D Kirn Journal: Gene Ther Date: 2001-05 Impact factor: 5.250
Authors: T L DeWeese; H van der Poel; S Li; B Mikhak; R Drew; M Goemann; U Hamper; R DeJong; N Detorie; R Rodriguez; T Haulk; A M DeMarzo; S Piantadosi; D C Yu; Y Chen; D R Henderson; M A Carducci; W G Nelson; J W Simons Journal: Cancer Res Date: 2001-10-15 Impact factor: 12.701
Authors: Svend O Freytag; Mark Khil; Hans Stricker; James Peabody; Mani Menon; Mariza DePeralta-Venturina; Daniel Nafziger; Jan Pegg; Dell Paielli; Steve Brown; Ken Barton; Mei Lu; Estuardo Aguilar-Cordova; Jae Ho Kim Journal: Cancer Res Date: 2002-09-01 Impact factor: 12.701
Authors: Oday Hamid; Mary L Varterasian; Scott Wadler; J Randolph Hecht; Al Benson; Evanthia Galanis; Margaret Uprichard; Charles Omer; Paul Bycott; Robert C Hackman; Anthony F Shields Journal: J Clin Oncol Date: 2003-04-15 Impact factor: 44.544
Authors: Abdellatif Bouazzaoui; Ahmed A H Abdellatif; Faisal A Al-Allaf; Neda M Bogari; Saied Al-Dehlawi; Sameer H Qari Journal: Pharmaceutics Date: 2021-01-22 Impact factor: 6.321
Authors: Sergiu Chira; Carlo S Jackson; Iulian Oprea; Ferhat Ozturk; Michael S Pepper; Iulia Diaconu; Cornelia Braicu; Lajos-Zsolt Raduly; George A Calin; Ioana Berindan-Neagoe Journal: Oncotarget Date: 2015-10-13
Authors: Yasha Li; Mengnan Liu; Jiejie Cui; Ke Yang; Li Zhao; Mengjia Gong; Yi Wang; Yun He; Tongchuan He; Yang Bi Journal: Oncol Lett Date: 2018-02-27 Impact factor: 2.967